Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49,779,938
-
Total 13F shares
-
52,784,275
-
Share change
-
-7,363,941
-
Total reported value
-
$546,345,758
-
Put/Call ratio
-
98%
-
Price per share
-
$10.35
-
Number of holders
-
117
-
Value change
-
-$76,354,796
-
Number of buys
-
43
-
Number of sells
-
58
Institutional Holders of Theravance Biopharma, Inc. - Common Stock (TBPH) as of Q2 2023
As of 30 Jun 2023,
Theravance Biopharma, Inc. - Common Stock (TBPH) was held by
117 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
52,784,275 shares.
The largest 10 holders included
Weiss Asset Management LP, BAUPOST GROUP LLC/MA, Madison Avenue Partners, LP, BlackRock Inc., VANGUARD GROUP INC, Irenic Capital Management LP, PICTET ASSET MANAGEMENT SA, Park West Asset Management LLC, Newtyn Management, LLC, and STATE STREET CORP.
This page lists
117
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.